The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNinety One Regulatory News (N91)

Share Price Information for Ninety One (N91)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 171.10
Bid: 170.90
Ask: 171.10
Change: 2.40 (1.42%)
Spread: 0.20 (0.117%)
Open: 175.00
High: 175.00
Low: 170.00
Prev. Close: 168.70
N91 Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Transaction in Own Shares

3 Nov 2023 07:05

RNS Number : 2433S
Ninety One PLC
03 November 2023
 

Ninety One plc ? ? Ninety One Limited

Incorporated in England and Wales ? Incorporated in the Republic of South Africa

Registration number 12245293 ? Registration number 2019/526481/06

Date of registration: 4 October 2019 ? Date of registration: 18 October 2019

LSE share code: N91 ? JSE share code: NY1

JSE share code: N91 ? ? ISIN: ZAE000282356

ISIN: GB00BJHPLV88

 

As part of the dual-listed company structure, the boards of Ninety One plc and Ninety One Limited (together the 'Board') notify both the London Stock Exchange and the JSE Limited ('JSE') of matters which are required to be disclosed under the FCA Disclosure Guidance and Transparency Rules and Listing Rules of the United Kingdom Listing Authority (the 'UKLA') and/or the JSE Listings Requirements (the 'Listing Requirements').

 

Ninety One Limited Ordinary Share Buyback

Ninety One Limited (the 'Company') advises that, at the close of business on 01 November 2023, it has cumulatively repurchased 8,900,922 of the Company's ordinary shares ('Ordinary Shares') representing 3.007% of the issued Ordinary Share capital as at the date of the general authority granted by shareholders at the Company's annual general meeting held on 26 July 2023 ('General Authority').

The Ordinary Shares were repurchased for an aggregate value of R345,632,678.38. Details of the repurchase are set out in the table hereunder:

 

Repurchase period

Number and percentage of shares repurchased

Highest repurchase price per share (R)

Lowest repurchase price per share (R)

Aggregate value (R)

Number and percentage of shares outstanding in relation to the total shares under the General Authority

27 July -

1 November 2023

8,900,922

3.007%

R40.00

R35.89

R345,632,678.38

20,695,450

6.993%

 

An application will be made to the JSE to de-list 307,360 Ordinary Shares, at which point they will be immediately cancelled. 8,593,562 Ordinary Shares have already been cancelled. The Ordinary Shares remaining in issue following the cancellation of the aforementioned shares amounts to 287,062,798. The Company does not hold any treasury shares.

 

The impact of the repurchase of the Ordinary Shares on the financial information of the Company is immaterial. The Ordinary Shares were repurchased from excess cash resources of the Company; going forward, no Ordinary Share dividends will be payable on the repurchased Ordinary Shares and interest earned on the cash utilised for the repurchases will be foregone. 

 

On 27 July 2023, in accordance with paragraph 5.72(h) of the JSE Listings Requirements, the Company entered into a mandate (the 'Mandate') with an independent agent to undertake its repurchase programme. Under the Mandate, the repurchase programme continued during the Company's closed period from 1 October to 15 November 2023. The repurchases were made in terms of the current General Authority effected through an order book operated by the JSE and executed without any prior understanding or arrangement between the Company and the counterparties. Accordingly, the Company has complied with paragraph 5.72(a) of the Listings Requirements.

 

 

Statement by the Board

The Board has considered the effect of the repurchases and is of the opinion that, for a period of 12 months following the repurchases, the:

? Company and its subsidiaries (the 'Group') will be able, in the ordinary course of business, to pay its debts;

? consolidated assets of the Company and the Group will be in excess of the consolidated liabilities;

? share capital and reserves of the Company and the Group will be adequate for ordinary business purposes; and

? working capital of the Company and the Group will be adequate for ordinary business purposes.

 

 

For enquiries please contact:

 

Investor relations

Alvar Fernandez alvar.fernandez@ninetyone.com +44 (0) 20 3938 2305

Jakub Vojtek jakub.vojtek@ninetyone.com +44 (0) 20 3938 2413

 

 

Date of release: ?03 November 2023

JSE Sponsor: J.P. Morgan Equities South Africa (Pty) Ltd

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
POSEAKFAEEEDFFA
Date   Source Headline
29th Apr 20241:00 pmRNSDealing in Securities by Employee Benefit Trusts
22nd Apr 20242:30 pmRNSDealing in Securities by Employee Benefit Trusts
16th Apr 20247:00 amRNSQ4 2024 AUM update
15th Apr 20242:00 pmRNSDealing in Securities by Employee Benefit Trusts
8th Apr 20242:00 pmRNSDealing In Securities by Employee Benefit Trusts
2nd Apr 20242:00 pmRNSDirector/PDMR Shareholding
28th Mar 20241:00 pmRNSDirector/PDMR Shareholding
22nd Mar 20241:00 pmRNSDirector/PDMR Shareholding
18th Mar 20242:00 pmRNSDealing In Securities by Employee Benefit Trusts
18th Mar 20242:00 pmRNSDealing In Securities by Employee Benefit Trusts
14th Mar 202412:00 pmRNSDirector/PDMR Shareholding
11th Mar 202412:00 pmRNSDirector/PDMR Shareholding
7th Mar 202412:00 pmRNSDirector/PDMR Shareholding
4th Mar 202412:00 pmRNSDirector/PDMR Shareholding
29th Feb 20242:00 pmRNSDirector/PDMR Shareholding
26th Feb 20242:00 pmRNSDirector/PDMR Shareholding
22nd Feb 20242:00 pmRNSDirector/PDMR Shareholding
20th Feb 20242:00 pmRNSHolding(s) in Company
15th Feb 20243:00 pmRNSDirector/PDMR Shareholding
15th Feb 20243:00 pmRNSHolding(s) in Company
8th Feb 20242:00 pmRNSDirector/PDMR Shareholding
6th Feb 20243:00 pmRNSHolding(s) in Company
5th Feb 20242:00 pmRNSDirector/PDMR Shareholding
1st Feb 20242:00 pmRNSDirector/PDMR Shareholding
31st Jan 20242:00 pmRNSDealing in Securities by Employee Benefit Trusts
31st Jan 20242:00 pmRNSDealing in Securities by Employee Benefit Trusts
29th Jan 20242:00 pmRNSDirector/PDMR Shareholding
25th Jan 20242:00 pmRNSDirector/PDMR Shareholding
18th Jan 20241:00 pmRNSDirector/PDMR Shareholding
16th Jan 20247:00 amRNSQ3 2024 AUM update
16th Jan 20247:00 amRNS2023 AGM - Voting Results Update
5th Jan 20242:00 pmRNSDirector/PDMR Shareholding
11th Dec 20232:30 pmRNSDirector/PDMR Shareholding
15th Nov 20237:00 amRNSHalf-year Report and Dividend Declaration
3rd Nov 20237:05 amRNSTransaction in Own Shares
17th Oct 20237:00 amRNS2nd Quarter Update
2nd Oct 20232:30 pmRNSDirector/PDMR Shareholding
28th Sep 20232:30 pmRNSDirector/PDMR Shareholding
26th Sep 20232:00 pmRNSDirector/PDMR Shareholding
21st Sep 20232:00 pmRNSDirector/PDMR Shareholding
18th Sep 20232:00 pmRNSDirector/PDMR Shareholding
14th Sep 20232:00 pmRNSDirector/PDMR Shareholding
13th Sep 20233:30 pmRNSCompany Secretary Change
11th Sep 20232:00 pmRNSDirector/PDMR Shareholding
7th Sep 20232:00 pmRNSDirector/PDMR Shareholding
29th Aug 20234:00 pmRNSHolding(s) in Company
24th Aug 20232:00 pmRNSDirector/PDMR Shareholding
24th Aug 20232:00 pmRNSDealing In Securities by Employee Benefit Trusts
21st Aug 20232:00 pmRNSDirector/PDMR Shareholding
17th Aug 20234:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.